A pharmaceutical company in northeast China's Heilongjiang Province has had a harsh punishment imposed for its mistake in improperly labeling its products, according to a statement on the website of the State Food and Drug Administration.

The Harbin Yida Pharmaceutical Co., Ltd was found to have mistakenly labeled its arsenious acid and sodium chloride injection by the provincial drug watchdog on Aug. 4.

The administration immediately asked the company to recall all injections in China which were produced since the beginning of 2009, although no case of adverse reactions have been reported.

This was a serious incident caused by the company's failure to implement safe production regulations and responsibilities, the statement said.

The statement also urged drug administrative agencies nationwide to conduct strict supervision and routine checks of production of medications by drug companies.

The mislabeled injection is mainly used to treat Promyelocytic leukemia, kalign lymphomas and in enhancing the effectiveness of radiotherapy.